Notably, our analysis of JMJD1C and RUNX1 expression across different genetic subtypes of AML patients from the STJUDE database (McLeod et al., 2021) revealed no preferential high expression of either gene in any particular subtype within the specific mutations examined (Fig. S1G). This evidence concerns the gene JMJD1C and acute myeloid leukemia.